Related references
Note: Only part of the references are listed.Myeloid somatic mutation panel testing in myeloproliferative neoplasms
David M. Ross et al.
PATHOLOGY (2021)
Mutational profiling in suspected triple-negative essential thrombocythaemia using targeted next-generation sequencing in a real-world cohort
Olga Michail et al.
JOURNAL OF CLINICAL PATHOLOGY (2021)
Cell-autonomous megakaryopoiesis associated with polyclonal hematopoiesis in triple-negative essential thrombocythemia
Tadaaki Inano et al.
SCIENTIFIC REPORTS (2021)
Novel drivers and modifiers of MPL-dependent oncogenic transformation identified by deep mutational scanning
Jessica L. Bridgford et al.
BLOOD (2020)
Whole-genome sequencing of patients with rare diseases in a national health system
Ernest Turro et al.
NATURE (2020)
MDS overlap disorders and diagnostic boundaries
Tiffany N. Tanaka et al.
BLOOD (2019)
The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution
Deepak Singhal et al.
LEUKEMIA (2019)
Two activating mutations of MPL in triple-negative myeloproliferative neoplasms
Juan Xie et al.
CANCER MEDICINE (2019)
Clonal hematopoiesis in human aging and disease
Siddhartha Jaiswal et al.
SCIENCE (2019)
Diagnostic workflow for hereditary erythrocytosis and thrombocytosis
Mary Frances McMullin
Hematology-American Society of Hematology Education Program (2019)
Mutant GNAS drives pancreatic tumourigenesis by inducing PKA-mediated SIK suppression and reprogramming lipid metabolism
Krushna C. Patra et al.
NATURE CELL BIOLOGY (2018)
Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms
William Vainchenker et al.
BLOOD (2017)
Identification of MPL R102p Mutation in Hereditary thrombocytosis
Christine Bellanne-Chantelot et al.
FRONTIERS IN ENDOCRINOLOGY (2017)
Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms
Jelena D. Milosevic Feenstra et al.
BLOOD (2016)
Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients
Xenia Cabagnols et al.
BLOOD (2016)
Oncogenic activation of MPL/thrombopoietin receptor by 17 mutations at W515: implications for myeloproliferative neoplasms
J-P Defour et al.
LEUKEMIA (2016)
Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence
Giulio Genovese et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Deep sequencing reveals double mutations in cis of MPL exon 10 in myelloproliferative neoplasm's
Daniela Pietra et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Familial thrombocytosis caused by the novel germ-line mutation p.Pro106Leu in the MPL gene
El-Harith Abdelghaffar El-Harith et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Compound heterozygous c-Mpl mutations in a child with congenital amegakaryocytic thrombocytopenia: Functional characterization and a review of the literature
Norma E. Fox et al.
EXPERIMENTAL HEMATOLOGY (2009)
Genetic profiling of myeloproliferative disorders by single-nucleotide polymorphism oligonucleotide microarray
Norihiko Kawamata et al.
EXPERIMENTAL HEMATOLOGY (2008)
Mpl Baltimore: A thrombopoietin receptor polymorphism associated with thrombocytosis
AR Moliterno et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Mutations in the thrombopoietin receptor, Mpl, in children with congenital amegakaryocytic thrombocytopenia
S van den Oudenrijn et al.
BRITISH JOURNAL OF HAEMATOLOGY (2000)
Share Paper
